Coloplast A/s Class B · OMXCOP:COLO_B

Coloplast A/s Class B — Investor Day (September 2009)

17 slides from Coloplast A/s Class B's investor day presentation, Sep 29, 2009

1. Slide 1: Leading Intimate Healthcare: Coloplast Capital Market Day 2009

   Coloplast Capital Market Day 2009 Leading Intimate Healthcare Coloplast p Capital p Market Day y 2009 Bjørn Christ, SVP ROW 29 September 2009 Leading Intimate Healthcare Page 1

2. Slide 2: Agenda

   Coloplast Capital Market Day 2009 Agenda • Creating the US platform • Opportunities & challenges in th US the • Execution is on track 29 September 2009 Leading Intimate Healthcare Page 2

3. Slide 3: The creation of today's US business platform required a three-step plan

   Coloplast Capital Market Day 2009 The creation of today today’s s US business platform required execution over a multi-year period on a three-step plan 1. Acquiring anchoring point -> Mentor 2. Focusing activities -> Minneapolis 3. Organizing for growth -> Organization & leadership 29 September 2009

4. Slide 4: Step 1. Acquired US anchoring point in the form of Mentor Urology

   Coloplast Capital Market Day 2009 Step 1. Acquired US anchoring point in the form of Mentor Urology Strategic rationale for move into Urology • Enlarging the scope of our continence care business into urology • A solid position in the US urology and continence markets • Strengthening of our European

5. Slide 5: Step 2. Relocated from 7 sites to new facilities in the Twin Cities

   Coloplast Capital Market Day 2009 Step 2. Relocated from 7 sites to new facilities in the Twin Cities Minneapolis, MN • Head quarter q • Manufacturing • Product Mankato, MN development • Manufacturing • Product development. development All positions moved to Amoena Breast Care Minneapolis divested M

6. Slide 6: Integration of Vadnais Heights with Mankato marks the end of restructuring

   Coloplast Capital Market Day 2009 Integration g of Vadnais Heights g with Mankato marks the end of restructuring 29 September 2009 Leading Intimate Healthcare Page 6

7. Slide 7: Step 3. Upgraded organization to a platform for sustained growth

   Coloplast Capital Market Day 2009 Step 3. Upgraded organization to a platform for sustained growth Positioning g for the future Consolidated Establish all US Dedicated Unify & strategic functions into surgical Upgrade marketing one business unit Sales Force capability organization 29 September 2009

8. Slide 8: Today, Coloplast US is right where it needs to be

   Coloplast Capital Market Day 2009 Today, Coloplast US is right where it needs to be Boston ev3 Techn. Scientific/ 420 empl. Medtronic SciMed EMPI 4,300 empl. ~2,000 empl. 500 empl. Smiths MD 380 empl. l Boston Scientific/ Enpath Guidant M di l Medical 3,000 empl. 380 empl. Minntech 3M AMS 380 empl.

9. Slide 9: Agenda

   Coloplast Capital Market Day 2009 Agenda • Creating the US platform • Opportunities & challenges in th US the • Execution is on track 29 September 2009 Leading Intimate Healthcare Page 9

10. Slide 10: Coloplast's industry segment drives down total healthcare cost

    Coloplast Capital Market Day 2009 Coloplast’s industry segment drives down total healthcare cost US healthcare spend distribution ESTIMATE Healthcare administration (~5%) US commercial US government • Health Maintenance Organization (HMO) • Preferred Provider Organization (PPO) • Medicaid • Insuranc

11. Slide 11: Coloplast's value proposition is proven: We lead Intimate Healthcare

    Coloplast Capital Market Day 2009 Coloplast’s p value p proposition p is p proven: We lead “Intimate Healthcare” ESTIMATE Hospital and professional Home & consumers Medical equipment Medical equipmentandanddevices devices (~2%) (89) Medical treatment P f Professional i l equipment i t and d devices

12. Slide 12: Coloplast's business areas have major US potential

    Coloplast Capital Market Day 2009 12 Coloplast’s business areas have major US potential ESTIMATE Market Growth Millions 900 Market Size 2008 Coloplast share 800 700 High High Mid Low Mid 600 500 400 300 200 100 0 Continence Urology Skin Care Ostomy Wound 29 September 2009 Leading Intimate Healthcare

13. Slide 13: Coloplast's competitors depend on their US success (and failure)

    Coloplast Capital Market Day 2009 Coloplast’s p competitors p depend p on their US success (and failure) VS. 29 September 2009 Leading Intimate Healthcare Page 13

14. Slide 14: Agenda

    Coloplast Capital Market Day 2009 Agenda • Creating the US platform • Opportunities & challenges in th US the • Execution is on track 29 September 2009 Leading Intimate Healthcare Page 14

15. Slide 15: Current momentum suggests Coloplast US is on track

    Coloplast Capital Market Day 2009 Current momentum suggests Coloplast US is on track 1. Fastest growing region 2. Active business areas growing double-digit 3. …with more scope to optimize execution 29 September 2009 Leading Intimate Healthcare Page 15

16. Slide 16: In summary, Coloplast US is on rails

    Coloplast Capital Market Day 2009 In summary, Coloplast US is on rails Completed US platform for growth Favorable market characteristics in all BA’s We have momentum 29 September 2009 Leading Intimate Healthcare Page 16

17. Slide 17: Coloplast Capital Market Day 2009

    Coloplast Capital Market Day 2009 ? ? ?? ? ? ? ? ? ? ? ? ? ?? ? ? 29 September 2009 Leading Intimate Healthcare Page 17

Coloplast — Investor Day (September 2009) on 6ix